Drugmaker Cipla has signed a perpetual license agreement with Novartis Pharma (Switzerland) to manufacture and market diabetes drug Galvus and its combination brands from January 1, 2026. 

One of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space, especially in the oral diabetic medication category, Galvus has the potential to contribute significantly to its portfolio with reported sales of Rs 268 crore, Cipla said citing IQVIA (MAT February 2023) numbers.

The agreement is subject to satisfaction of certain conditions precedent. During the interim Cipla will continue to market and distribute Galvus-branded products. This deal is expected to further bolster Cipla’s position in India as one of the top players in the diabetes category.